Literature DB >> 17627490

National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness- Alzheimer's Disease (CATIE-AD): baseline characteristics.

M Saleem Ismail1, Karen Dagerman, Pierre N Tariot, Shana Abbott, Sarah Kavanagh, Lon S Schneider.   

Abstract

CATIE-AD was a multicenter effectiveness trial of atypical antipsychotics in patients with agitation and psychosis associated with AD who resided in the community. The study enrolled 421 participants. In this paper we present and discuss baseline characteristics of participants (demographics, cognitive, behavioral, and functional assessments), caregivers (demographics and caregiver burden) and settings at randomization. Those enrolled suffered from a wide range of cognitive impairment, were medically complex and experienced acute psychopathology requiring intervention with atypical antipsychotics. Family members providing the equivalent of institutional care experienced significant depression and caregiver burden. With the increasing prevalence of AD, clinicians and health care planners should look into future needs of those AD sufferers who are residing in community.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17627490     DOI: 10.2174/156720507781077214

Source DB:  PubMed          Journal:  Curr Alzheimer Res        ISSN: 1567-2050            Impact factor:   3.498


  4 in total

1.  Effect of second-generation antipsychotics on caregiver burden in Alzheimer's disease.

Authors:  Somaia Mohamed; Robert Rosenheck; Constantine G Lyketsos; Richard Kaczynski; David L Sultzer; Lon S Schneider
Journal:  J Clin Psychiatry       Date:  2011-09-06       Impact factor: 4.384

Review 2.  Dependence as a unifying construct in defining Alzheimer's disease severity.

Authors:  Trent McLaughlin; Howard Feldman; Howard Fillit; Mary Sano; Frederick Schmitt; Paul Aisen; Christopher Leibman; Lisa Mucha; J Michael Ryan; Sean D Sullivan; D Eldon Spackman; Peter J Neumann; Joshua Cohen; Yaakov Stern
Journal:  Alzheimers Dement       Date:  2010-11       Impact factor: 21.566

3.  Clinical symptom responses to atypical antipsychotic medications in Alzheimer's disease: phase 1 outcomes from the CATIE-AD effectiveness trial.

Authors:  David L Sultzer; Sonia M Davis; Pierre N Tariot; Karen S Dagerman; Barry D Lebowitz; Constantine G Lyketsos; Robert A Rosenheck; John K Hsiao; Jeffrey A Lieberman; Lon S Schneider
Journal:  Am J Psychiatry       Date:  2008-06-02       Impact factor: 18.112

4.  The price of progress: Funding and financing Alzheimer's disease drug development.

Authors:  Jeffrey Cummings; Carl Reiber; Parvesh Kumar
Journal:  Alzheimers Dement (N Y)       Date:  2018-06-13
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.